Boston Scientific, Axonics Merger Prompts FTC to Request Additional Information
By Denny Jacob
Boston Scientific and Axonics each received a request for additional information from the Federal Trade Commission regarding a previously agreed upon merger.
The medical device manufacturer in January agreed to acquire Axonics for about $3.7 billion in cash, resulting in Axonics becoming a wholly-owned subsidiary of Boston Scientific.
The additional request for information extends the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 until 30 days after both sides have substantially complied with the request, Boston Scientific said in a securities filing.
The merger is now expected to be completed in the second half of 2024.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
April 04, 2024 08:00 ET (12:00 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Markets Brief: Tech Stocks Lead Ahead of Nvidia Earnings
-
How Anti-Obesity Drugs Are Innovating the Healthcare Market
-
What’s Happening In the Markets This Week
-
Why Immigration Has Boosted Job Gains and the Economy
-
What to Invest in During High Inflation
-
Never Mind Market Efficiency: Are the Markets Sensible?
-
Starbucks Stock Could Use a Pick-Me-Up After Big Selloff; Is it a Buy?
-
5 Cheap Stocks to Buy From an Attractive Part of the Market
-
Should You Buy and Hold an Artificial Intelligence Portfolio?
-
3 Cheap and Dependable Dividend-Growth Stocks to Buy
-
The Best Bank Stocks to Buy
-
After Earnings, Is Roblox Stock a Buy, Sell, or Fairly Valued?
-
After Earnings, Is Lyft Stock a Buy, a Sell, or Fairly Valued?
-
8 Stock Picks in the Apparel Industry
-
Baidu Earnings: Advertising Weakness Offset by Continued Growth In Cloud Business
-
Going Into Earnings, Is Target Stock a Buy, a Sell, or Fairly Valued?